#1
#1 out of 186.56%
health1h ago
New Ozempic-Style Pill Outperformed Oral Semaglutide in Major Trial
- Orforglipron significantly outperformed oral semaglutide in the ACHIEVE-3 phase 3 trial for type 2 diabetes, with greater glycemic improvements and more weight loss.
- The ACHIEVE-3 trial tracked participants across 131 centers for one year to evaluate efficacy and safety.
- Safety signals showed higher gastrointestinal events and discontinuations with orforglipron compared with oral semaglutide.
- Orforglipron does not need to be taken on an empty stomach, offering a practical usability advantage over some semaglutide regimens.
- Regulatory approval is still required before orforglipron becomes widely available, though the drug is nearing pivotal steps in clinical development.
- The study suggests orforglipron could surpass semaglutide in treating type 2 diabetes and may extend to obesity treatment.
- The Lancet published the ACHIEVE-3 trial results, highlighting their significance for GLP-1 therapies.
Vote 0